Wan Qin Chong

1 Introduction First-line standard-of-care (SOC) treatment for recurrent/metastatic nasopharyngeal carcinoma (NPC) is cisplatin plus gemcitabine; however, the 12-month progression-free survival (PFS) rate is only 20% [1, 2]. Recently, the anti-programmed cell death protein 1 (PD-1) inhibitor toripalimab in combination with cisplatin and gemcitabine was approved by the US Food and Drug Administration as a first-line treatment option for this patient population [3, 4].

Research Article Wan Qin Chong, Chwee Ming Lim, Arvind Kumar Sinha, Chee Seng Tan, Gloria Hui Jia Chan, Yiqing Huang, Nesaretnam Barr Kumarakulasinghe, Raghav Sundar, Anand D Jeyasekharan, Woei Shyang Loh, Joshua K Tay, Kritika Yadav, Lingzhi Wang, Andrea L Wong, Li Ren Kong, Ross Andrew Soo, Jieying Amelia Lau, Yu Yang Soon, Robby Miguel Goh, Francis Cho Hao Ho, Siew Meng Chong, Soo-Chin Lee, Kwok Seng Loh, Bee Choo Tai, Yaw Chyn Lim and Boon Cher Goh DOI: 10.1158/1078-0432.CCR-20-1727...